Want to see IN:AKUMS full AI Analyst Report?
AKUMS Stock Chart & Stats
₹420.10
₹13.30(2.17%)
At close: 4:00 PM EST
₹420.10
₹13.30(2.17%)
Day’s Range― - ―
52-Week Range₹410.10 - ₹713.80
Previous CloseN/A
Volume56.90K
Average Volume (3M)11.50K
Market Cap
₹107.48B
Enterprise Value₹56.30K
Total Cash (Recent Filing)₹16.78B
Total Debt (Recent Filing)₹902.87M
Price to Earnings (P/E)41.0
Beta1.32
Next Earnings
Aug 24, 2026EPS Estimate
6.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)12.42
Shares Outstanding157,393,980
10 Day Avg. Volume12,021
30 Day Avg. Volume11,497
Financial Highlights & Ratios
PEG Ratio-1.07
Price to Book (P/B)2.15
Price to Sales (P/S)1.64
P/FCF Ratio7.28
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)23.95
Revenue Forecast (FY)₹49.24B
Bulls Say, Bears Say
Bulls Say
Balance Sheet DeleveragingThe company materially reduced leverage to very low debt-to-equity levels in FY25–FY26 and expanded equity, providing a stronger capital base. This durable improvement lowers refinancing risk, increases financial flexibility for capex or M&A, and supports resiliency through industry cycles.
Stronger Cash GenerationSubstantially positive operating and free cash flow in FY26, with FCF covering a large portion of earnings, signals improved cash conversion and internal funding capacity. Durable cash generation supports reinvestment, working-capital needs and reduces dependence on external financing over the medium term.
Revenue Growth & CDMO ModelConsistent top-line growth plus a contract development/manufacturing business model serving multiple therapeutic categories creates recurring demand and diversification. Structural outsourcing trends in pharma and a broad finished-dosage capability support sustainable revenue streams and repeat client volumes.
Bears Say
Margin Compression In FY26A sharp drop in gross and net margins in FY26 indicates material cost, mix or pricing pressures that reduced profitability. If structural (commodity, pricing pressure or unfavorable mix), sustained compression would erode returns, cash generation and the benefits of a stronger balance sheet over months.
Historical Cash/earnings VolatilityAlthough cash flow strengthened recently, the company has a history of uneven operating cash conversion and a year-over-year FCF decline in FY26 versus FY25. Persistent volatility undermines reliable internal funding and complicates medium-term planning for capex, dividends or debt reduction.
Customer/contract Disclosure OpacityThe business relies on third-party manufacturing for client brands but provides no detail on customer concentration or contracted revenue. That opacity raises structural client-concentration and renegotiation risks, which can materially affect revenues and margins if major clients reduce volumes or change terms.
Akums Drugs and Pharmaceuticals Limited News
AKUMS FAQ
What was Akums Drugs and Pharmaceuticals Limited’s price range in the past 12 months?
Akums Drugs and Pharmaceuticals Limited lowest stock price was ₹410.10 and its highest was ₹713.80 in the past 12 months.
What is Akums Drugs and Pharmaceuticals Limited’s market cap?
Akums Drugs and Pharmaceuticals Limited’s market cap is ₹107.48B.
When is Akums Drugs and Pharmaceuticals Limited’s upcoming earnings report date?
Akums Drugs and Pharmaceuticals Limited’s upcoming earnings report date is Aug 24, 2026 which is in 38 days.
How were Akums Drugs and Pharmaceuticals Limited’s earnings last quarter?
Akums Drugs and Pharmaceuticals Limited released its earnings results on May 14, 2026. The company reported ₹5.5 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Akums Drugs and Pharmaceuticals Limited overvalued?
According to Wall Street analysts Akums Drugs and Pharmaceuticals Limited’s price is currently Overvalued.
Does Akums Drugs and Pharmaceuticals Limited pay dividends?
Akums Drugs and Pharmaceuticals Limited pays a N/A dividend of ₹3 which represents an annual dividend yield of N/A. See more information on Akums Drugs and Pharmaceuticals Limited dividends here
What is Akums Drugs and Pharmaceuticals Limited’s EPS estimate?
Akums Drugs and Pharmaceuticals Limited’s EPS estimate is 6.1.
How many shares outstanding does Akums Drugs and Pharmaceuticals Limited have?
Akums Drugs and Pharmaceuticals Limited has 157,393,980 shares outstanding.
What happened to Akums Drugs and Pharmaceuticals Limited’s price movement after its last earnings report?
Akums Drugs and Pharmaceuticals Limited reported an EPS of ₹5.5 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.69%.
Which hedge fund is a major shareholder of Akums Drugs and Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in IN:AKUMS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Akums Drugs and Pharmaceuticals Limited
Akums Drugs & Pharmaceuticals Ltd. is an Indian-based company, established in 2004 and headquartered in Delhi, that operates globally as a manufacturer and supplier of both finished pharmaceutical products and active pharmaceutical ingredients (APIs). Its diverse product range encompasses conventional drugs, traditional Ayurvedic and herbal remedies, personal care items including toiletries, nutraceuticals, food and dietary supplements, dermatological and cosmetic products, and healthcare and hospital supplies, along with over-the-counter (OTC) solutions. The company also deals in excipients and various chemical compounds. Akums develops and markets its own branded formulations across a variety of dosage forms, such as tablets, capsules, injectables, ophthalmic preparations, and soft gelatin capsules. These products address a broad spectrum of therapeutic areas, including gynaecology, cardiology, orthopaedics, pediatrics, dermatology, anti-infectives, pain management, and gastroenterology. Furthermore, Akums Drugs & Pharmaceuticals provides services as a pharmaceutical contract development and manufacturing organization (CDMO).
Technical Analysis
Glenmark Life Sciences Limited
―
Jubilant Pharmova Limited
―
Shilpa Medicare Limited
―
Strides Pharma Science Ltd
―
Sudeep Pharma Limited
―